Aveanna Healthcare Holdings Inc (AVAH) Return on Equity ROE from the second quarter 2026 to second quarter 2025 and annually, average high and low, overall ranking from Jul 04 2026 to Jun 28 2025 - CSIMarket
CSIMarket Company Name, Ticker, Competitors, else..
 


• ROA Quarterly
• ROI Quarterly
• ROE Quarterly
Aveanna Healthcare Holdings Inc   (NASDAQ: AVAH)
    Sector • Healthcare    Industry • Healthcare Facilities
   Industry • Healthcare Facilities
   Sector • Healthcare

Aveanna Healthcare Holdings Inc 's ROE per quarter

Return on Equity, Quarterly Results, Trends, Rankings, Statistics


What is ROE for Aveanna Healthcare Holdings Inc in the second quarter 2026?
Aveanna Healthcare Holdings Inc achieved a return on average equity (ROE) of 150.35 % in its second quarter 2026, this is above AVAH's average return on equity of -31.38%.
Aveanna Healthcare Holdings Inc shareholder's equity over the 12 months ending in its second quarter 2026 are valued at $183 million

ROE decreased relative to the period ending , due to the decline in net income.

Within the Healthcare Facilities industry Aveanna Healthcare Holdings Inc achieved the highest return on equity. While Return on equity, overall ranking has advanced in the quarter, so far to 34, from total ROE ranking in the first quarter 2026 at 557.

What is ROE?



Download as CSV
Commercial Data Licensing & OEM
Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms
API & Data Feeds
Programmatic access to normalized fundamentals & ratios.

Return On Equity (Jul 04 2026)
II. Quarter		 (Apr 04 2026)
I. Quarter		 (Jan 03 2026)
IV. Quarter		 (Sep 27 2025)
III. Quarter		 (Jun 28 2025)
II. Quarter
Y / Y Equity Change - - - - -
Y / Y Net Income Change 49.1 % 702.1 % 512.58 % - 94.34 %
Net Income (TTM) in Millions 275 261 225 75 19
Return On Equity (TTM) 150.35 % 242.29 % 983.51 % - -
AVAH's Total Ranking # 34 # 557 # 2593 # 0 # 0
Equity (TTM) in Millions 287 240 194 9 -12
Seq. Equity Change 19.67 % 23.44 % 2017.39 % - -
Seq. Net Income Change -3.27 % -76.7 % 1170.99 % -47.96 % 420.41 %

Back to AVAH Management Effectiveness >> AVAH's 5 Years Annual ROE >> Compare AVAH ROE to its Competitors
Return On Equity Company Ranking
Within: No.
Industry # 1
Sector # 10
Overall # 34

Return On Equity Statistics
High Average Low
983.51 %
-31.38 %
-745.63 %
(Jan 03 2026)   (Apr 01 2023)





AVAH Annual Return On Equity (Jan 03 2026)
2026		 (Dec 28 2024)
2024		 (Dec 30 2023)
2023		 (Dec 31 2022)
2022
Total Equity in Millions 194 -124 -130 -6 0
Y / Y Equity Change - - - - -
Net Income in Millions 225 -11 -135 -662 0
Y / Y Net Income Change - - - - -
Return On Equity 115.72 % - - - -

Back to AVAH Management Effectiveness >> AVAH's 5 Years Annual ROE >> Compare AVAH ROE to its Competitors




Annual Roe Comment
In 2026 ROE fell to 115.72 %, despite net income growth.


More Return On Equity Ratios
Healthcare Facilities Industry Roe Trends and Statistics
Healthcare Sector Return On Equity Statistics
AVAH's' Return on Equity at Yahoo Finance
AVAH's Roe Ratio versus Healthcare Facilities Industry, Healthcare Sector and overall Market
Highest Ranking Return On Equity
Lowest Ranking Return On Equity
Subscribers only: Roe for AVAH's Competitors
Subscribers only: Roe for Aveanna Healthcare Holdings Inc 's Suppliers
Subscribers only: Return On Equity for AVAH's Customers




Companies with similar Return On Equity at Jul 04 2026, within Healthcare Sector ROE
Meiragtx Holdings Plc  283.67 %
Silexion Therapeutics Corp  276.59 %
Actinium Pharmaceuticals Inc  213.46 %
Halozyme Therapeutics Inc   180.63 %
Capforce Inc   168.50 %
Aveanna Healthcare Holdings Inc   150.35 %
Liquidia Corporation  149.64 %
Interpace Biosciences Inc   142.98 %
Oncotelic Therapeutics Inc   124.17 %
Fortress Biotech Inc   118.22 %
Medpace Holdings Inc   110.15 %
Pulmatrix Inc   108.83 %
Arbutus Biopharma Corp  106.04 %
Rigel Pharmaceuticals Inc  96.49 %
Exelixis Inc   93.62 %
Alnylam Pharmaceuticals Inc   93.61 %
Eli Lilly And Company  92.54 %
Amgen Inc   89.32 %
Q32 Bio Inc   76.88 %
3m Company  76.55 %
Oramed Pharmaceuticals Inc  73.03 %
Tg Therapeutics Inc   72.30 %
Idexx Laboratories Inc  71.96 %
Elite Pharmaceuticals Inc   71.10 %
Zoetis Inc   68.87 %
Rallybio Corporation  68.56 %
Earth Science Tech Inc   66.17 %
Aurinia Pharmaceuticals Inc   59.00 %
Vaxart Inc   53.04 %
Qhslab Inc   51.21 %

Date modified: 2026-09-26T07:39:23+00:00



Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.